Showing results (101-110 of 134) with videos related to
Sort By:
Pageof 14
Journal of Clinical Medicine|October 16, 2025
Outcomes in Asymptomatic Patients Undergoing Coronary Revascularization Before Liver TransplantationGoyal Umadat, Jennifer Lee, Jordan C Ray, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|March 1, 1996
Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancerB D Curti, W J Urba, D L Longo, et al.Blood|November 26, 2010
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSPWei Ju, Meili Zhang, Jian-kang Jiang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meetingKunihiro Tsukasaki, Olivier Hermine, Ali Bazarbachi, et al.Proceedings of the National Academy of Sciences of the United States of America|January 3, 2006
Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemiaJohn C Morris, John E Janik, Jeffrey D White, et al.Blood|March 27, 2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinomaJ E Janik, L L Miller, E L Korn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2016
Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphomaKamal Sharma, John E Janik, Deirdre O'Mahony, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignanciesDeirdre O'Mahony, John C Morris, Maryalice Stetler-Stevenson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid TumorsOmid Hamid, Dana B Cardin, F Stephen Hodi, et al.Blood|July 30, 2010
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19James N Kochenderfer, Wyndham H Wilson, John E Janik, et al.Pageof 14